Novian Health

  • About Us
    • Overview
    • Management
    • Board Of Directors
    • Investors
  • Research & Products
    • Novilase® Breast Therapy
    • Clinical Trials & Registries
    • Publications
    • Intellectual Property
  • News
    • News & Press Releases
    • Media Coverage
    • Upcoming Events
  • Contact
    • Careers

Novian Health Named Finalist for the 2014 Red Herring Top 100 North America Award (16 May 2014)

May 16, 2014 by Novian Health

May 16, 2014
Contact: Liz Dowling, (415) 388-­‐2794
Dowling & Dennis Public Relations
E-­mail: Liz@DowlingDennis.net

Laser ablation medical device company recognized as one of the most Promising Private Companies in North American Region

CHICAGO – Novian Health, developer of Novilase® Breast Therapy, announced today that it has been selected as a finalist for Red Herring’s Top 100 North America award, a prestigious list honoring the year’s most promising private technology ventures from the North American business region.

“It is an honor to be recognized by Red Herring,” said Henry “Chip” Appelbaum, Novian Health’s President and CEO.“With our laser technology, we hope to improve the treatment of early‐stage breast cancer for women and make it more effective and less traumatic than surgery.

We’re making progress in that direction through our Novilase Clinical Trial that’s currently underway in breast cancer centers throughout the U.S. and Europe.”

The Red Herring Top 100 award highlights the most exciting startups from Asia, Europe and the Americas. Hundreds of companies from each region are reviewed in a rigorous three-­step process that examines the companies’ technological innovation, management strength, market size, investor record, customer acquisition and financial health.

Applicants for the award included companies from the fields of security, Web 2.0, software, hardware, life sciences, cloud, and mobile, among others.

Red Herring is a global media company that unites the world’s best high technology innovators, venture investors and business decision makers in a variety of forums: a leading innovation magazine, an online daily technology news service, technology newsletters and major events for technology leaders around the globe.

About Novilase

Novilase Breast Therapy is a laser-based,minimally invasive device for destroying tumors. It provides an alternative to conventional surgery while preserving the patient’s options for additional procedures or adjunctive therapies. The image-guided outpatient procedure does not require general anesthetic or a hospital stay.

About Novian Health

Novian Health Inc., based in Chicago with a subsidiary in Evry, France, is a privately held medical device company with proprietary technology for the treatment of tumors using Interstitial Laser Therapy. Developed as an alternative to surgery,the company’s technology uses parametrically controlled heating for the ablation of tumors. Image-guided treatment of breast tumors is the first application of the technology, with the potential for Novilase to treat tumors elsewhere in the body. Novian Health has received U.S. FDA 510(k) clearance for the treatment of benign breast tumors. For more information, call (312) 266-7200 or access www.novianhealth.com.

Related Posts

  • Novian Health President & CEO Interviewed by Med Device Insights (01 Dec 2014)
  • Novian Health Presents at William Blair Private Conference
  • Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors (2 Sept 2014)
  • Novian Health Announces Agreement with Rose Medical Center in Denver
  • Novian Health Announces Agreement with Tower Radiology Center in Tampa Bay

Filed Under: Press Release 2014

Recent Posts

  • Novian Health Earns New Product Innovation Award for Novilase Breast Therapy (6 December 2022)
  • Novian Health Gains FDA Breakthrough Designation for Novilase Breast Therapy (28 September 2021)
  • Novian Health Inc. Announces the Second Close of Convertible Note Financing (23 August 2021)
  • Novian Health Inc. Announces the First Close of Convertible Note Financing (28 July 2021)
  • Novian Health to Present at the Cavendish Global Summit on February 25, 2021 (12 February 2021)

ARCHIVES

  • December 2022
  • September 2021
  • August 2021
  • July 2021
  • February 2021
  • September 2020
  • June 2020
  • September 2019
  • July 2019
  • June 2019
  • December 2015
  • December 2014
  • September 2014
  • May 2014
  • December 2013
  • April 2013
  • February 2013
  • April 2012
  • October 2011
  • September 2011
  • July 2011
  • November 2010
  • December 2009
  • November 2009
  • October 2009
  • May 2009
  • June 2008
  • March 2008
  • October 2007
  • June 2007

Categories

  • Archives
  • Press Release 2011
  • Press Release 2012
  • Press Release 2013
  • Press Release 2014
  • Press Release 2015
  • Press Release 2019
  • Press Release 2020
  • Press Release 2021
  • Press Release 2022

CONTACT US

Novian Health Inc.
(Headquarters)
Novian Health Inc.
(Manufacturing)
222 W Merchandise Mart Plaza
Suite 1230
Chicago, Illinois 60654
1205 E State Avenue
Tonganoxie, KS 66086
Office: 312-266-7200 Office: 312-266-7200
Fax: 312-266-7202 Fax: 312-266-7202
Email: info@novianhealth.com Email: info@novianhealth.com

    

LATEST NEWS

  • Novian Health Earns New Product Innovation Award for Novilase Breast Therapy (6 December 2022)
  • Novian Health Gains FDA Breakthrough Designation for Novilase Breast Therapy (28 September 2021)
  • Novian Health Inc. Announces the Second Close of Convertible Note Financing (23 August 2021)
  • Novian Health Inc. Announces the First Close of Convertible Note Financing (28 July 2021)
  • Novian Health to Present at the Cavendish Global Summit on February 25, 2021 (12 February 2021)

Copyright © 2023 Novian Health. All Rights Reserved. Powered by